" class="no-js "lang="en-US"> Greg Piefer - Medtech Alert
Wednesday, August 13, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Greg Piefer

Greg Piefer

About Greg Piefer

I am hard working and motivated, especially when I can see a long-term strategy that benefits from that work. I have a strong desire to commercialize near-term nuclear technologies that make the world a better place for all. I have a long term dream to commercialize nuclear fusion energy.

Related Story

Fundraising

 SHINE Medical Technologies Closes $150-million Series C-5 Financing to Advance Nuclear Fusion-Based Technologies | Pharmtech Focus

SHINE Medical Technologies Closes $150-million Series C-5 Financing to Advance Nuclear Fusion-Based Technologies

June 30 2021

SHINE Medical Technologies LLC today announced that it has closed a $150-million Series C-5 financing. […]